Key result
Smoking cessation after a first CV event is linked to a ~34% reduction in recurrent MACE.
Why the study?
The study was conducted to quantify the relation between smoking cessation after a first cardiovascular event and the risk of recurrent cardiovascular events and mortality.
Does smoking cessation reduce recurrent MACE and all-cause mortality in patients with a recent first manifestation of arterial disease?
Cohort (n=4,673)
Does smoking cessation reduce recurrent MACE and all-cause mortality in patients with a recent first manifestation of arterial disease?
Effect estimate: HR 0.66 (95% CI 0.49-0.88)
Smoking cessation after a first cardiovascular event is associated with a 34% reduction in recurrent MACE and a 37% reduction in all-cause mortality, extending life by an average of 5 years.
No takes yet. Share an insight, caveat, or question.
May support intensified cessation counseling post-event; extends observational data but leaves causal benefit open for trials.
Berg et al. (2019) conducted a cohort in First manifestation of arterial disease (n=4,673). Smoking cessation vs. Continued smoking was evaluated on Recurrent major atherosclerotic cardiovascular events (MACE including stroke, MI and vascular mortality) (HR 0.66, 95% CI 0.49-0.88). Smoking cessation after a first cardiovascular event was associated with a lower risk of recurrent MACE compared to continued smoking (adjusted HR 0.66; 95% CI 0.49-0.88).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: